Clinical Trials Arena on MSN
Kainova reports positive top line results from Phase I EPRAD trial
The study demonstrated a favourable safety profile for DT-9081.
Notes: 1) Efficacy population (n=39), includes all randomized participants who received at least one dose of study drug and had a valid baseline and post-baseline body weight assessment. 2) ...
– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also ...
SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE)-- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or "the Company”), today announced that the Independent Data Monitoring Committee (IDMC) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results